CP0 en es it fr

CP0 Brand names, CP0 Analogs

CP0 Brand Names Mixture

  • No information avaliable

CP0 Chemical_Formula

C33H38N4O6

CP0 RX_link

http://www.rxlist.com/cgi/generic2/irinot.htm

CP0 fda sheet

CP0 FDA

CP0 msds (material safety sheet)

CP0 MSDS

CP0 Synthesis Reference

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

CP0 Molecular Weight

586.678 g/mol

CP0 Melting Point

222-223 oC

CP0 H2O Solubility

Soluble

CP0 State

Solid

CP0 LogP

4.372

CP0 Dosage Forms

Solution for IM injection

CP0 Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

CP0 Pharmacology

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

CP0 Absorption

100%

CP0 side effects and Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

CP0 Patient Information

CP0 Organisms Affected

Humans and other mammals